Table 2: Serum Oxidative Stress Markers and HSA Status in HD Patients with sHPT.

Serum Marker
(Unit)
HD Patients with Calcitriol Therapy
Mean ±SD (95% CI)
p Value
Pre-treatment
(Baseline)
Post-treatment
8 Weeks 16 Weeks
IS (µg/ml) 74.066±15.65
(65.4 - 82.7)
77.13±14.9
(68.85 - 85.41)
79.0±13.73 *
(71.39 - 86.6)
* 0.01
SOD (ng/ml) 387.87±106.3
(329.0 - 446.7)
623.9±156.9 **
(537.0 - 710.8)
601.9±160.1 **
(513.25 - 690.6)
** 0.001
HNA (%) 62.356±4.3
(59.96 - 64.7)
48.36±4.56 **
(45.83 - 50.88)
52.9±6.03 ** ##
(49.57 - 56.26)
** 0.001
## 0.002
HMA (%) 37.51±4.38
(35.08 - 39.93)
51.64±4.56 **
(49.1 - 54.17)
46.4±4.64 ** ##
(43.8 - 48.98)
** 0.001
## 0.001
HNA/HMA (ratio) 1.68±0.3
(1.514 - 1.85)
2.006±2.94
(0.376 - 3.64)
1.15±0.21 **
(1.04 - 1.27)
** 0.001

Data: Expressed as mean ±SD (95%CI of mean)Markers: SOD: Superoxide dismutase, IS: Indoxyl Sulfate, HNA: Human non-mercaptoalbumin, HMA: Human mercaptoalbumin, HNA/HMA: Oxidized albumin ratio The comparison between means was assessed using Wilcoxon Signed Rank test at 16 weeks post treatment was considered significant at p Value: * <0.05 & ** <0.005 compared to pre-treatment and ##<0.005 compared to 8 weeks post-treatment.